Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Synthesis against the clock


Novel radiopharmaceutical for the diagnosis of tumor-relevant transport proteins developed

Radiolabeled molecules, so-called radiotracers, help nuclear physicians to detect and precisely target tumors, which are often developing due to pathological changes in metabolic processes. Using positron emission tomography, a team of scientists at Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has now developed the first radiotracer labelled with the fluorine isotope 18F, which can visualize special transport proteins often found in the cell membranes of cancer cells.

(From left): Dr. Daniel Gündel, Dr. Masoud Sadeghzadeh, Dr. Magali Toussaint, Dr. Barbara Wenzel, Dr. Winnie Deuther-Conrad, Dr. Rares-Petru Moldovan, Dr. Friedrich-Alexander Ludwig and Prof. Peter Brust.

Credit: HZDR/ Bodo Tiedemann

(From right:) Dr. Barbara Wenzel and Dr. Masoud Sadeghzadeh in the synthesis lab.

Credit: HZDR/ Bodo Tiedemann

The researchers opted for an unusual radiochemical synthesis approach, as they describe in the journal Scientific Reports (DOI: 10.1038/s41598-019-55354-w).

During metabolism, malignant tumors generate increased amounts of a certain type of transport protein, which, for example, transports the intermediate metabolic product, lactate, into certain tumor cells while simultaneously exporting it away from others - a strategy to prevent apoptosis, a form of programmed cell death that would kill the tumor in a healthy metabolism.

"This correlation has been observed in a variety of tumor types. For this reason, so-called monocarboxylate transporters are considered as key proteins for treating a broad spectrum of different kinds of cancer. Manipulating them can lead to a successful therapy," explains Prof. Peter Brust. He is the head of the Department of Neuroradiopharmaceuticals at the HZDR research site in Leipzig and works on current radiopharmaceutical topics with a focus on brain research. "This includes the synthetic development of modern radiotracers, which play a special role in battling cancer and, in particular, aggressive brain tumors," says Peter Brust, outlining his team's mission.

In molecular-biological and preclinical studies, scientists had already tried to block the activity of monocarboxylate transporters (MCT) by using certain small organic molecules with a pronounced inhibitory effect (for example, α-CHC). Initial results showed that interrupting lactate flow can be a highly effective therapeutic strategy to stunt the growth of malignant tumors.

Radiopharmaceuticals for non-invasive imaging

In addition to its therapeutic interest, the metabolic function of MCT also opens up new diagnostic possibilities: They can be used as valuable biomarkers in many types of cancer, for example by using positron emission tomography (PET). This method uses radionuclides emitting positively charged elementary particles, called positrons. The patient is first given a radiopharmaceutical, a molecule coupled with a radioactive atom such as 18F, which emits positrons. As a positron interacts with an electron in the body, radiation is emitted in diametrically opposed directions in the form of two high-energy photons, which are recorded by detectors arranged in a ring around the patient. This image of the metabolic processes allows physicians to draw conclusions about the spatial distribution of the radiopharmaceutical inside the body, and thus, about any pathological changes.

Objective: Rapid, automated radiopharmaceutical synthesis for everyday clinical use

Despite their potential as therapeutic target structures in the fight against cancer, hardly any radiolabeled MCT inhibitors have recently been studied to gauge their suitability in diagnostic imaging procedures such as PET. "We have now developed a structural analog of the known MCT inhibitor α-CHC and successfully coupled it with the PET radionuclide 18F in a complex procedure. Its relatively short half-life of 110 minutes ensures that the patient can tolerate the radiation exposure," says Dr. Masoud Sadeghzadeh, who coordinated the experiments, describing the approach used by the Leipzig chemists.

After conducting the first promising preclinical studies of their new compound [18F]FACH, the scientists revised their synthetic pathway. "The challenge is to produce the radiotracer fast enough so we can harness the radiating properties of 18F in practical applications," radiochemist Dr. Barbara Wenzel explains. The timespan during which the radiotracer is usable is determined by the half-life of the radionuclide. While the chemists initially needed 160 minutes to manually produce the new radiotracer, they were now able to reduce the synthesis time by half by modifying their approach..

"The key feature of our synthesis is that it does not require the addition of a protective group. This now obsolete intermediate step used to be necessary to protect the reactive parts of a molecule from unintended side reactions," Barbara Wenzel adds. The scientists have thus considerably simplified the procedure and adapted it for the transfer to an automated synthesis module - an indispensable prerequisite for the tumor examinations that are now planned as well as for possible future use in nuclear medicine.



M. Sadeghzadeh, R.-P. Moldovan, R. Teodoro, P. Brust, B. Wenzel: One-step radiosynthesis of the MCTs imaging agent [18F]FACH by aliphatic 18F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group, Scientific Reports, 2019 (DOI: 10.1038/s41598-019-55354-w)

M. Sadeghzadeh, R.-P. Moldovan, S. Fischer, B. Wenzel, F.-A. Ludwig, R. Teodoro, W. Deuther-Conrad, S. Jonnalagadda, S. K. Jonnalagadda, E. Gudelis, A. Šačkus, Kei Higuchi, V. Ganapathy, V. R. Mereddy, L. R. Drewes, P. Brust: Development and radiosynthesis of the first 18F-labeled inhibitor of monocarboxylate transporters (MCTs), Journal of Labelled Compounds and Radiopharmaceuticals, 2019 (DOI: 10.1002/jlcr.3739)

Additional information:

Dr. Barbara Wenzel | Dr. Masoud Sadeghzadeh | Prof. Peter Brust
Institute of Radiopharmaceutical Cancer Research at HZDR, Leipzig site
Phone: +49 0351 260-4637 | -4630 | -4610
Mail: | |

Media contact:

Simon Schmitt | Science editor
Phone: +49 351 260-3400 | Email:
Helmholtz-Zentrum Dresden-Rossendorf | Bautzner Landstr. 400 | 01328 Dresden / Germany |

The Helmholtz-Zentrum Dresden-Rossendorf (HZDR) performs - as an independent German research center - research in the fields of energy, health, and matter. We focus on answering the following questions:

· How can energy and resources be utilized in an efficient, safe, and sustainable way?

· How can malignant tumors be more precisely visualized, characterized, and more effectively treated?

· How do matter and materials behave under the influence of strong fields and in smallest dimensions?

To help answer these research questions, HZDR operates large-scale facilities, which are also used by visiting researchers: the Ion Beam Center, the High-Magnetic Field Laboratory Dresden, and the ELBE Center for High-Power Radiation Sources.

HZDR is a member of the Helmholtz Association and has five sites (Dresden, Freiberg, Grenoble, Leipzig, Schenefeld near Hamburg) with almost 1,200 members of staff, of whom about 500 are scientists, including 170 Ph.D. candidates.

You receive this mail as a service offer from the Helmholtz-Zentrum Dresden-Rossendorf. If you don't want to get this service, please reply to this mail with the subject "unsubscribe".

Media Contact

Simon Schmitt


Simon Schmitt | EurekAlert!

More articles from Life Sciences:

nachricht Quick notes in the genome
07.07.2020 | Max-Planck-Institut für molekulare Genetik

nachricht Limitations of Super-Resolution Microscopy Overcome
07.07.2020 | Julius-Maximilians-Universität Würzburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Excitation of robust materials

Kiel physics team observed extremely fast electronic changes in real time in a special material class

In physics, they are currently the subject of intensive research; in electronics, they could enable completely new functions. So-called topological materials...

Im Focus: Electrons in the fast lane

Solar cells based on perovskite compounds could soon make electricity generation from sunlight even more efficient and cheaper. The laboratory efficiency of these perovskite solar cells already exceeds that of the well-known silicon solar cells. An international team led by Stefan Weber from the Max Planck Institute for Polymer Research (MPI-P) in Mainz has found microscopic structures in perovskite crystals that can guide the charge transport in the solar cell. Clever alignment of these "electron highways" could make perovskite solar cells even more powerful.

Solar cells convert sunlight into electricity. During this process, the electrons of the material inside the cell absorb the energy of the light....

Im Focus: The lightest electromagnetic shielding material in the world

Empa researchers have succeeded in applying aerogels to microelectronics: Aerogels based on cellulose nanofibers can effectively shield electromagnetic radiation over a wide frequency range – and they are unrivalled in terms of weight.

Electric motors and electronic devices generate electromagnetic fields that sometimes have to be shielded in order not to affect neighboring electronic...

Im Focus: Gentle wall contact – the right scenario for a fusion power plant

Quasi-continuous power exhaust developed as a wall-friendly method on ASDEX Upgrade

A promising operating mode for the plasma of a future power plant has been developed at the ASDEX Upgrade fusion device at Max Planck Institute for Plasma...

Im Focus: ILA Goes Digital – Automation & Production Technology for Adaptable Aircraft Production

Live event – July 1, 2020 - 11:00 to 11:45 (CET)
"Automation in Aerospace Industry @ Fraunhofer IFAM"

The Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM l Stade is presenting its forward-looking R&D portfolio for the first time at...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

International conference QuApps shows status quo of quantum technology

02.07.2020 | Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Latest News

Quick notes in the genome

07.07.2020 | Life Sciences

Limitations of Super-Resolution Microscopy Overcome

07.07.2020 | Life Sciences

Put into the right light - Reproducible and sustainable coupling reactions

07.07.2020 | Life Sciences

Science & Research
Overview of more VideoLinks >>>